CAR T cell therapy revolutionizes oncology by using engineered T cells to target and eliminate cancer cells, improving ...

Introduction: T cell activation requires T cell receptor (TCR) engagement by its specific ligand. This interaction initiates a series of proximal events including tyrosine phosphorylation of the CD3 ...

Venetoclax is under clinical development by AbbVie and currently in Phase I for Primary Mediastinal B-Cell Lymphoma.

Cellular research indicates that neuropilin-1 plays a crucial role in pain signaling, presenting a potential pathway for ...

The study highlights adhesion G-protein-coupled receptor A3 (ADGRA3) as a potential target for activating adaptive ... and hesperetin in inducing the development of beige adipocytes through the ...

B-Cell Receptor (BCR) Signaling and Ibrutinib What B cells do in their normal ... However, B-cell lymphomas often hijack this normal BCR signaling pathway to take advantage of this pre-existing ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Peptides, as versatile biological molecules, have garnered significant attention in scientific research due to their ...

One avenue for this ambition is cell receptors, which function like ignition slots on a cell, requiring keys—such as specific hormones, drugs, or antigens—to start up specific cellular activities.